Table 1.
Patient pre-treatment characteristics.
| CON (n = 75) | SEQ (n = 71) | |
|---|---|---|
| Age | ||
| Median (range) | 67 (48, 82) | 63 (45, 77) |
| Gender | ||
| Male | 40 (53%) | 43 (61%) |
| Female | 35 (47%) | 28 (39%) |
| Karnofsky performance status | ||
| 100 | 17 (23%) | 18 (25%) |
| 90 | 33 (44%) | 22 (31%) |
| 80 | 19 (25%) | 20 (28%) |
| 70 | 6 (8%) | 11 (15%) |
| ECOG performance status | ||
| 0 | 33 (44%) | 30 (43%) |
| 1 | 38 (51%) | 39 (56%) |
| 2 | 4 (5%) | 1 (1%) |
| Unknown | 0 | 1 |
| Site of primary tumour | ||
| Head | 35 (47%) | 34 (48%) |
| Body | 19 (25%) | 20 (28%) |
| Tail | 21 (28%) | 17 (24%) |
| Liver metastases | ||
| No | 13 (17%) | 11 (15%) |
| Yes | 62 (83%) | 60 (85%) |
| CA19.9 (U/ml) | ||
| Median (range) | 4032 (1.0, 275228) | 2377 (4.0, 217920) |
| <ULN | 9 (13%) | 9 (13%) |
| ≥ULN | 59 (87%) | 60 (87%) |
| Unknown | 7 | 2 |
| C-reactive protein (mg/l) | ||
| Median (range) | 9.0 (0.8, 249) | 11.0 (0.3, 208) |
| Unknown | 5 | 1 |
| Neutrophil count (109/l) | ||
| Median (range) | 5.3 (1.6, 19.3) | 6.1 (2.6, 22.4) |